CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MindBio Therapeutics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MindBio Therapeutics Corp
1055 West Georgia Street
1500 Royal Centre
VANCOUVER, BC  V6E 4N7  Canada Ticker: MBIOMBIO
Business Summary
MindBio Therapeutics Corp. is a biotechnology company. The Company is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. It has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. It has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The Company invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Business Names
Business Name
MBIO
WF6

General Information
Outstanding Shares: 135,047,305 (As of 4/16/2024)
Stock Exchange: CNQ
Email Address: info@mindtherapeutics.com.au


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024